Comparison
Gonadorelin vs. Oxytocin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
33515-09-2
50-56-6
Molecular weight
1182.29 g/mol
1007.19 g/mol
Half-life
0.1 h
0.05 h
Sequence
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2Mechanism of action
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Oxytocin
Oxytocin is synthesised in the hypothalamus and released via the posterior pituitary. Peripherally it binds the oxytocin receptor, a G-protein-coupled receptor, and through the phospholipase-C cascade and calcium release triggers contraction of uterine smooth muscle and milk ejection — the pharmacological basis of the obstetric approval. Centrally, oxytocin acts as a neuromodulator and has been linked to social bonding, trust and modulation of stress and anxiety circuits. Its central effects in humans are mechanistically incompletely understood, particularly because it is unclear to what extent peripherally or intranasally administered oxytocin crosses the blood-brain barrier.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
4
4
Effects recorded
4
3
Open conflicts
1
1
Documented adverse events
2
0
Legal status
Full entries
Frequently asked questions
- What is the difference between Gonadorelin and Oxytocin?
- Gonadorelin is classified as "Research other", while Oxytocin is classified as "Research other". Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. Oxytocin: Oxytocin is an endogenous nonapeptide hormone of the posterior pituitary. In synthetic form (Pitocin, Syntocinon) it has been approved for decades to induce and augment labour and to control postpartum uterine bleeding. Strictly separate from this is intranasal use to influence social behaviour, trust, anxiety or autism symptoms: this use is unapproved, purely experimental, and yields inconsistent and often negative results in controlled trials. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Gonadorelin or Oxytocin?
- The highest available evidence level is "Human trial" for Gonadorelin and "Human RCT" for Oxytocin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Gonadorelin and Oxytocin in Germany and the United States?
- Germany: Gonadorelin — Prescription, Oxytocin — Prescription. United States: Gonadorelin — Prescription, Oxytocin — Prescription. These are factual summaries with source and review date on the individual pages.